Evidence map›Paper›PMID 33796464›Full record

ArticleFrontiers in oncology2021

Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling.

Maria A Pantaleo, Marcella Mandruzzato, Valentina Indio, Milena Urbini, Margherita Nannini, Lidia Gatto, Angela Schipani, Michelangelo Fiorentino, Tania Franceschini, Valentina Ambrosini and 7 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Maria A PantaleoDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Marcella MandruzzatoDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Valentina Indio"Giorgio Prodi Cancer Research Center" and Department of Experimental, Diagnostic and Specialized Medicine, University of Bologna, Bologna, Italy.
Milena UrbiniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.
Margherita NanniniDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Lidia GattoDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Angela Schipani"Giorgio Prodi Cancer Research Center" and Department of Experimental, Diagnostic and Specialized Medicine, University of Bologna, Bologna, Italy.
Michelangelo FiorentinoMetropolitan Department of Pathology, University of Bologna, Bologna, Italy.
Tania FranceschiniMetropolitan Department of Pathology, University of Bologna, Bologna, Italy.
Valentina AmbrosiniDivision of Nuclear Medicine Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Valerio Di ScioscioDivision of Radiology Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Maristella SaponaraDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Manuela Ianni"Giorgio Prodi Cancer Research Center" and Department of Experimental, Diagnostic and Specialized Medicine, University of Bologna, Bologna, Italy.
Sergio ConcettiUOC Urologia, Azienda Unità Sanitaria Locale (AUSL), Bologna, Italy.
Annalisa AltimariDivision of Laboratory of Oncologic Molecular Pathology, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Andrea ArdizzoniDivision of Oncology, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Annalisa AstolfiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Azienda USL di Bologna · ITUniversity of Bologna · ITAzienda Unità Sanitaria Locale Della Romagna · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatic malignant transformation in a germ cell tumor (GCT) is the development of non-germ malignancies; much of available literature refers to teratoma with malignant transformation (TMT). There are various transformation histologies such as sarcoma, adenocarcinoma, primitive neuroectodermal tumors, and more rarely carcinoid tumors, hemangioendothelioma, lymphoma, or nephroblastoma. The treatments of these entities include surgery and/or chemotherapy. A standard approach in choosing chemotherapy in TMT cases has not yet been established. Many authors suggest using chemotherapeutic agents based on the transformed histology, while others recommend GCT-oriented therapy combined with surgery as the primary treatment, reserving histology-driven chemotherapies for metastatic relapse. We report the clinical findings and the genomic profile of a mixed GCT case with somatic-type malignancy of sarcoma type. We achieved a complete radiological response with GCT-oriented chemotherapy performed as salvage therapy after sarcoma-histology therapy. In addition, molecular profiles with RNA-sequencing and exome sequencing analyses of the primary tumor and the tumor with somatic-type malignancy of sarcoma type were explored.

Indexed as

exome sequencinggerm cell tumorPEBRNA-sequencingsarcomateratoma with malignant transformation

Identifiers

PMID33796464
PMCPMC8008106
OpenAlexW3136948365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.